Approach to the Patient Who Is Intolerant of Statin Therapy
Open Access
- 1 May 2010
- journal article
- case report
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (5), 2015-2022
- https://doi.org/10.1210/jc.2009-2689
Abstract
Myopathy occurs in approximately 10% of statin-treated patients and is most commonly manifested by myalgias with or without plasma creatine kinase (CK) elevations. Predisposition exists in patients treated with high doses of potent statins and those who are older, female, have a genetic predisposition, and when statins are coadministered with drugs that compete with or inhibit drug metabolism. In symptomatic patients, CK levels may assist in guiding management. If less than five times the upper limit of normal, the existing statin should be titrated to achieve cholesterol goals and the CK repeated when symptoms appear or worsen. In patients with moderate to severe symptoms and any patient with CK elevated to more than 5-fold the upper limit of normal, the statin should be stopped. Once asymptomatic and CK is reduced (if elevated previously), cholesterol goals can be approached by: 1) a different statin (e.g. fluvastatin or pravastatin), starting with a low dose and titrating up; 2) an alternate daily or weekly more potent statin (e.g. rosuvastatin or atorvastatin); or 3) the combination of the lowest tolerated statin with a cholesterol absorption inhibitor (ezetimibe) and/or bile acid sequestrant. Over-the-counter preparations, e.g. red yeast rice, containing natural statin-like agents, or plant sterols can also lower cholesterol. These, however, have limited efficacy to achieve targeted cholesterol levels for most patients. In patients without CK elevations and symptoms, progress can be followed clinically, but in patients who show CK elevations, CK should be monitored. At present, the superiority of one approach has not been demonstrated, and the need for clinical trials in well-characterized patients with statin intolerance cannot be dismissed.Keywords
This publication has 60 references indexed in Scilit:
- The safety of statins in clinical practiceThe Lancet, 2007
- The broad spectrum of statin myopathy: from myalgia to rhabdomyolysisCurrent Opinion in Lipidology, 2007
- Risks Associated With Statin TherapyCirculation, 2006
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task ForceThe American Journal of Cardiology, 2006
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004
- A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering DrugsCardiovascular Drugs and Therapy, 2003
- Muscular Side Effects of StatinsJournal of Cardiovascular Pharmacology, 2002
- ACC/AHA/NHLBI clinical advisory on the use and safety of statinsJournal of the American College of Cardiology, 2002
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002